Traders should monitor upcoming regulatory engagement on setrusumab despite missed primary endpoints, as secondary data may support approval. The extended cash runway reduces near-term dilution risk, but lack of primary endpoint success limits upside unless partnership or regulatory pathway emerges.
Price Chart
Executive Summary
Mereo BioPharma reported its 2025 financial results, showing a narrower net loss of $41.9 million compared to $43.3 million in 2024, with $41.0 million in cash as of year-end, providing a runway into mid-2027. The company disclosed that setrusumab failed to meet primary endpoints in Phase 3 trials for osteogenesis imperfecta but showed positive secondary outcomes including improved bone density and patient-reported benefits. Partnering discussions for alvelestat and development plans for vantictumab are progressing.
Key Financial Metrics
Key Facts
- Setrusumab Phase 3 trials did not meet primary endpoints (fracture rate reduction) but achieved statistically significant improvement in bone mineral density and patient-reported outcomes.
- Cash balance of $41.0 million as of December 31, 2025, down from $69.8 million, expected to fund operations into mid-2027.
- Net loss decreased to $41.9 million in 2025 from $43.3 million in 2024.
- R&D expenses decreased by $3.2 million year-over-year, driven by lower alvelestat costs, partially offset by higher setrusumab spending.
- Company continues active partnering discussions for alvelestat in AATD-LD and plans a Phase 2b trial in bronchiectasis to de-risk development.
- āshibio plans to initiate a Phase 2 trial of vantictumab in osteopetrosis in H2 2026, funding the global program.
Financial Impact
Cash decreased by $28.8 million YoY; net loss improved by $1.4 million; R&D down $3.2 million; $41.0M cash supports operations into mid-2027.
Risk Factors
- Setrusumab failed primary endpoints, increasing regulatory uncertainty despite positive secondary data.
- No revenue beyond minimal $500K in 2025, with no near-term commercial catalysts.
- Dependence on partnerships for alvelestat and vantictumab development increases execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258998 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | 8-K | $0.3115 $0.2780 | ▲ +10.75% | ▲ +10.37% | $0.2905 (+6.74%) |
Aug 11, 2026 11w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2905 (−5.07%) |
Aug 11, 2026 11w ago | Press Release | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2905 (−5.07%) |
Aug 11, 2026 11w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2905 (−5.07%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.3118 $0.3100 | ▼ −0.58% | ▼ −1.01% | $0.2905 (−6.83%) |
May 12, 2026 24w ago | Press Release | $0.2460 $0.2370 | ▲ +3.66% | ▲ +3.74% | $0.2905 (−18.09%) |
Mar 19, 2026 31w ago | Press Release | $0.3610 $0.3390 | ▼ −6.09% | ▼ −3.88% | $0.2905 (−19.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers